Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3898 USD | -7.19% | -92.58% | -92.56% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 1.57M | Sales 2025 * | 672K | Capitalization | 23.76M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -75M | EV / Sales 2024 * | 15.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 35.4 x |
P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.42
x | Employees | 88 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.92% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -7.19% | ||
1 week | -92.58% | ||
Current month | -92.45% | ||
1 month | -92.36% | ||
3 months | -91.90% | ||
6 months | -86.70% | ||
Current year | -92.56% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.3898 | -7.19% | 7,478,887 |
24-05-07 | 0.42 | -19.46% | 19,067,445 |
24-05-06 | 0.5215 | -87.06% | 108,645,212 |
24-05-03 | 4.03 | -12.96% | 2,439,825 |
24-05-02 | 4.63 | -11.81% | 582,604 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.56% | 25.61M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- LYRA Stock